Verzenios EU-godkänt för adjuvant behandling av HR+/HER2-, node positiv, bröstcancer
Adjuvant behandling med abemaciclib i kombination med endokrin behandling, minskade risken för återfall i bröstcancer med 32 %.
Läs mer...Lilly
Optimizing Treatment for ER+/HER2- mBC patients with aggressive disease
We are pleased to invite you for the next MBC TALKS webinar and live Q&A session where Prof. Gilles Freyer, Prof. Joyce A. O’Shaughnessy, Prof. Patrick Neven and Prof. Michael Untch will discuss different CDK4&6i data from both efficacy & safety stand point and how that can help improve patient outcome.
Läs mer...Continuing Advances in mBC – Not all CDK4&6i are the same
We are pleased to invite you for the next MBC TALKS webinar and live Q&A session where Prof. Gilles Freyer, Prof. Joyce A. O’Shaughnessy, Prof. Patrick Neven and Prof. Michael Untch will discuss different CDK4&6i data from both efficacy & safety standpoint and how that can help improve.
Läs mer...Continuing Advances in mBC: Optimizing CDK4&6 Inhibitor Treatment Outcomes
We are pleased to invite you for the next MBC TALKS webinar and live Q&A session where Prof. Eva Ciruelos, Prof. Marc Thill and Maria Noblet R.N. will discuss different CDK4&6i trials from an endocrine resistance perspective.
Läs mer...The CDK4/6 landscape when treating elderly MBC women
Härmed inbjuds du att delta vid ett webinar med fokus på behandling av äldre patienter med metastaserad bröstcancer […]
Läs mer...
